Tempus AI (NASDAQ:TEM) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Tempus AI (NASDAQ:TEM) issued its quarterly earnings data on Monday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.18), Zacks reports.

Tempus AI Stock Performance

Shares of TEM stock traded up $1.48 during trading hours on Monday, hitting $69.57. The stock had a trading volume of 17,573,282 shares, compared to its average volume of 14,454,233. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a one year low of $22.89 and a one year high of $91.45. The stock’s 50-day moving average price is $50.29 and its two-hundred day moving average price is $51.82.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. William Blair downgraded shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Bank of America upped their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and an average target price of $58.55.

Insider Activity at Tempus AI

In other news, Director Jennifer A. Doudna sold 1,320 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $90.00, for a total value of $118,800.00. Following the sale, the director now directly owns 36,011 shares in the company, valued at $3,240,990. The trade was a 3.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,583,467 shares of company stock valued at $130,542,311.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.